200 related articles for article (PubMed ID: 22072709)
1. Quality control of fungus-specific glucosylceramide in Cryptococcus neoformans by endoglycoceramidase-related protein 1 (EGCrP1).
Ishibashi Y; Ikeda K; Sakaguchi K; Okino N; Taguchi R; Ito M
J Biol Chem; 2012 Jan; 287(1):368-381. PubMed ID: 22072709
[TBL] [Abstract][Full Text] [Related]
2. Sterylglucoside catabolism in Cryptococcus neoformans with endoglycoceramidase-related protein 2 (EGCrP2), the first steryl-β-glucosidase identified in fungi.
Watanabe T; Ito T; Goda HM; Ishibashi Y; Miyamoto T; Ikeda K; Taguchi R; Okino N; Ito M
J Biol Chem; 2015 Jan; 290(2):1005-19. PubMed ID: 25361768
[TBL] [Abstract][Full Text] [Related]
3. Methylation of glycosylated sphingolipid modulates membrane lipid topography and pathogenicity of Cryptococcus neoformans.
Singh A; Wang H; Silva LC; Na C; Prieto M; Futerman AH; Luberto C; Del Poeta M
Cell Microbiol; 2012 Apr; 14(4):500-16. PubMed ID: 22151739
[TBL] [Abstract][Full Text] [Related]
4. Transmembrane transporter expression regulated by the glucosylceramide pathway in Cryptococcus neoformans.
Singh A; Rella A; Schwacke J; Vacchi-Suzzi C; Luberto C; Del Poeta M
BMC Res Notes; 2015 Nov; 8():681. PubMed ID: 26572681
[TBL] [Abstract][Full Text] [Related]
5. Glucosylceramide Administration as a Vaccination Strategy in Mouse Models of Cryptococcosis.
Mor V; Farnoud AM; Singh A; Rella A; Tanno H; Ishii K; Kawakami K; Sato T; Del Poeta M
PLoS One; 2016; 11(4):e0153853. PubMed ID: 27082428
[TBL] [Abstract][Full Text] [Related]
6. Surface localization of glucosylceramide during Cryptococcus neoformans infection allows targeting as a potential antifungal.
Rhome R; Singh A; Kechichian T; Drago M; Morace G; Luberto C; Del Poeta M
PLoS One; 2011 Jan; 6(1):e15572. PubMed ID: 21283686
[TBL] [Abstract][Full Text] [Related]
7. Fungal Glycolipid Hydrolase Inhibitors and Their Effect on Cryptococcus neoformans.
Santana AG; Tysoe C; Hu G; Kronstad J; Goddard-Borger ED; Withers SG
Chembiochem; 2017 Feb; 18(3):284-290. PubMed ID: 27905163
[TBL] [Abstract][Full Text] [Related]
8. Glucosylceramide synthase is an essential regulator of pathogenicity of Cryptococcus neoformans.
Rittershaus PC; Kechichian TB; Allegood JC; Merrill AH; Hennig M; Luberto C; Del Poeta M
J Clin Invest; 2006 Jun; 116(6):1651-9. PubMed ID: 16741577
[TBL] [Abstract][Full Text] [Related]
9. Changes in glucosylceramide structure affect virulence and membrane biophysical properties of Cryptococcus neoformans.
Raj S; Nazemidashtarjandi S; Kim J; Joffe L; Zhang X; Singh A; Mor V; Desmarini D; Djordjevic J; Raleigh DP; Rodrigues ML; London E; Del Poeta M; Farnoud AM
Biochim Biophys Acta Biomembr; 2017 Nov; 1859(11):2224-2233. PubMed ID: 28865794
[TBL] [Abstract][Full Text] [Related]
10. Functions and applications of glycolipid-hydrolyzing microbial glycosidases.
Ishibashi Y
Biosci Biotechnol Biochem; 2022 Jul; 86(8):974-984. PubMed ID: 35675217
[TBL] [Abstract][Full Text] [Related]
11. Cryptococcal virulence: beyond the usual suspects.
Mitchell AP
J Clin Invest; 2006 Jun; 116(6):1481-3. PubMed ID: 16741574
[TBL] [Abstract][Full Text] [Related]
12. The
Dai GY; Yin J; Li KE; Chen DK; Liu Z; Bi FC; Rong C; Yao N
J Biol Chem; 2020 Jan; 295(3):717-728. PubMed ID: 31819005
[TBL] [Abstract][Full Text] [Related]
13. Mismatch Repair of DNA Replication Errors Contributes to Microevolution in the Pathogenic Fungus
Boyce KJ; Wang Y; Verma S; Shakya VPS; Xue C; Idnurm A
mBio; 2017 May; 8(3):. PubMed ID: 28559486
[TBL] [Abstract][Full Text] [Related]
14. Cell wall alpha-1,3-glucan is required to anchor the Cryptococcus neoformans capsule.
Reese AJ; Doering TL
Mol Microbiol; 2003 Nov; 50(4):1401-9. PubMed ID: 14622425
[TBL] [Abstract][Full Text] [Related]
15. Role of the fungus-specific flavin carrier Flc1 in antifungal resistance in the fungal pathogen Cryptococcus neoformans.
Zhang P; Li C; Huo L; Xiang B; Rahim K; Hao X; Zhu X
Med Mycol; 2019 Jun; 57(4):468-477. PubMed ID: 30010978
[TBL] [Abstract][Full Text] [Related]
16.
Chitty JL; Blake KL; Blundell RD; Koh YQAE; Thompson M; Robertson AAB; Butler MS; Cooper MA; Kappler U; Williams SJ; Kobe B; Fraser JA
J Biol Chem; 2017 Jul; 292(28):11829-11839. PubMed ID: 28559277
[TBL] [Abstract][Full Text] [Related]
17. Structural analysis of glucosylceramides (GlcCer) from species of the Pseudallescheria/Scedosporium complex.
Calixto RO; Rollin-Pinheiro R; da Silva MI; Liporagi-Lopes LC; Vieira JM; Sassaki GL; Barreto-Bergter E
Fungal Biol; 2016 Feb; 120(2):166-72. PubMed ID: 26781373
[TBL] [Abstract][Full Text] [Related]
18. Network-assisted genetic dissection of pathogenicity and drug resistance in the opportunistic human pathogenic fungus Cryptococcus neoformans.
Kim H; Jung KW; Maeng S; Chen YL; Shin J; Shim JE; Hwang S; Janbon G; Kim T; Heitman J; Bahn YS; Lee I
Sci Rep; 2015 Mar; 5():8767. PubMed ID: 25739925
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibody to fungal glucosylceramide protects mice against lethal Cryptococcus neoformans infection.
Rodrigues ML; Shi L; Barreto-Bergter E; Nimrichter L; Farias SE; Rodrigues EG; Travassos LR; Nosanchuk JD
Clin Vaccine Immunol; 2007 Oct; 14(10):1372-6. PubMed ID: 17715331
[TBL] [Abstract][Full Text] [Related]
20. Dietary sericin enhances epidermal levels of glucosylceramides and ceramides with up-regulating protein expressions of glucosylceramide synthase, β-glucocerebrosidase and acidic sphingomyelinase in NC/Nga mice.
Kim H; Lee J; Cho Y
Nutr Res; 2012 Dec; 32(12):956-64. PubMed ID: 23244541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
